DNDN: Dendreon Cp - Full Company Report
Enter Ticker:
Dendreon Corporation discovers and develops immunologically based therapeutic products for the treatment of cancer. Through the use of antigen engineering and proprietary cell separation technologies, Dendreon develops therapeutic vaccines that induce cell-mediated immunity, the body's key defense against cancer. In addition to its products for cancer, Dendreon also intends to pursue the application of its technologies in the fields of autoimmune diseases, allergies and infectious diseases.
General Information
DENDREON CORP
3005 First Avenuewww.dendreon.com ir@dendreon.com
Industry
MED-BIOMED/GENE
Sector:
Medical
Fiscal Year End
December
Last Reported Quarter
09/30/09
Next EPS Date
03/11/2010
Price and Volume Information
Zacks Rank
Yesterday's Close
27.54
52 Week High
30.42
52 Week Low
2.55
Beta
4.33
20 Day Moving Average
2,535,959.50
Target Price Consensus
34.8
% Price Change
4 Week
1.16
12 Week
17.79
YTD
511.57
% Price Change Relative to S&P 500
4 Week
0.06
12 Week
11.05
YTD
406.15
Share Information
Shares Outstanding (millions)
115.75
Market Capitalization (millions)
3,242.05
Short Ratio
2.50
Last Split Date
N/A
Dividend Information
Dividend Yield
0.00%
Annual Dividend
$0.00
Payout Ratio
0.00
Change in Payout Ratio
0.00
Last Dividend Payout / Amount
NA / $0.00
EPS Information
Current Quarter EPS Consensus Estimate
-0.29
Current Year EPS Consensus Estimate
-1.64
Estimated Long-Term EPS Growth Rate
-
Next EPS Report Date
03/11/2010
Consensus Recommendations
Current (1=Strong Buy, 5=Strong Sell)
1.50
30 Days Ago
1.50
60 Days Ago
1.83
90 Days Ago
1.91
Fundamental Ratios
P/E
Current FY Estimate:
-
Trailing 12 Months:
-
PEG Ratio
-
EPS Growth
vs. Previous Year
-37.93%
vs. Previous Quarter
66.67%
Sales Growth
vs. Previous Year
-3.85%
vs. Previous Quarter:
0.00%
Price Ratios
Price/Book
27.25
Price/Cash Flow
-
Price / Sales
30,018.94
ROE
09/30/09
-254.45
06/30/09
-344.38
03/31/09
-319.85
ROA
09/30/09
-82.72
06/30/09
-95.39
03/31/09
-50.79
Current Ratio
09/30/09
-
06/30/09
2.41
03/31/09
4.07
Quick Ratio
09/30/09
-
06/30/09
2.41
03/31/09
4.07
Operating Margin
09/30/09
-188,528.72
06/30/09
-169,575.23
03/31/09
-67,836.37
Net Margin
09/30/09
-181,935.19
06/30/09
-163,036.69
03/31/09
-61,372.72
Pre-Tax Margin
09/30/09
-181,935.19
06/30/09
-163,036.69
03/31/09
-61,372.72
Book Value
09/30/09
1.03
06/30/09
1.41
03/31/09
0.14
Inventory Turnover
09/30/09
-
06/30/09
-
03/31/09
-
Debt-to-Equity
09/30/09
0.44
06/30/09
0.38
03/31/09
6.97
Debt to Capital
09/30/09
30.63
06/30/09
27.67
03/31/09
87.45
Sponsored Links 
-0.34